

Sheet



PTO/S8/08a (11-08

Approved for use through 12/31/2008. OMS 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Complete If Known

 Application Number
 09/925,284-Conf. #2660

 Filing Date
 August 9, 2001

 First Named Inventor
 Daniel Hawiger

 At Ust
 1644

 Examiner Name
 R.B. Schwadron

 Altowny Dockst Number
 RUJ-0010NCPRCE2

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> ( If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-4,474,893	10-02-1984	Reading	
	A2*	US-4,946,778	08-07-1990	Ladner et al.	-
	A3*	US-4,954,617	09-04-1990	Fanger et al.	
	A4*	US-5,455,030	10-03-1995	Ladner et al.	
	A5*	US-5,476,786	12-19-1995	Huston	
	A6*	US-5,545,807	08-13-1996	Surani et al.	
	A7*	US-5,698,679	12-16-1997	Nemazee	
	A8*	US-5,869,057	02-09-1999	Rock	
	A9*	US-5,876,917	03-02-1999	Hart et al.	
	A10*	US-5,922,845	07-13-1999	Deo et al.	
	A11*	US-6,080,409	06-27-2000	Laus et al.	
	A12*	US-6,277,959	08-21-2001	Valladeau et al.	
	A13*	US-6,340,569	01-22-2002	Ball et al.	
	A14*	US-6,479,247-A1	11-12-2002	Hart et al.	
	A15*	US-20020187131-A1	12-12-2002	Hawiger et al.	
	A16*	US-6,756,478-A1	06-29-2004	Valladeau et al.	
	A17*	US-20040001853-A1	01-01-2004	George et al.	1

	FOREIGN PATENT DOCUMENTS									
Examiner Initals*	Cite No.1	Foreign Patent Document Country Code* - Number* - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	7				
	B1	WO-86/01533-A1	03-13-1986	Celltech Limited		Г				
	B2	WO-88/00052-A1	01-14-1988	Trustees of Dartmouth College		Γ				
	Вз	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation		Γ				
	B4	WO-92/03918-A1	03-19-1992	Genpharm International, Inc.		Γ				
	B5	WO-93/04187-A1	03-04-1993	Medical Research Council		Γ				
	B6	WO-93/12227-A1	06-24-1993	Genpharm International, Inc.		Γ				

Examiner	/Ronald Schwadron/	Date	06/10/2010
Signature	TIOTICIA CONTRACTOR	Considered	00/19/2010

\*\*EXAMINE: this if reference considered, whether or not calcure is conference with NED (90). The lie through abdomin in cell in reference considered, leaded on considered, leaded on considered, leaded on considered, leaded on the considered on the control of the form whether communitation be inpliced. "OTE NO TOWN experienced; which the single selected," I refer to the Cite No. are not supplied (under 37 CFR 1 50(a)(2)(3)) because that application was fine after June 30, 2003 or is available in the FW 1 Applicant is reason addition designed number of particular to the Cite No. are not supplied (under 37 CFR 1 50(a)(2)(3)) because that application was fine after all 20, 2003 or is available in the FW 1 Applicant is reason additional control on article (see 1 miles) and the Cite No. 2003 or is available in the FW 1 Applicant is precised in serial in miles of the partie of community. The control of the community o

Express Mail Label No	FM 19	22 977 47	2115	Dated-	Eabruani 20	2000

819833-1

Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

0.1.11	ute for form 1449/P	10		Complete If Known		
Substitu	ute for form 1449/F	10		Application Number	09/925,284-Conf. #2660	
INF	ORMATI	ON DISC	LOSURE	Filing Date	August 9, 2001	
			PLICANT	First Named Inventor	Daniel Hawiger	
• • • • • • • • • • • • • • • • • • • •				Art Unit	1644	
	(Use as man	y sheets as nec	essary)	Examiner Name	R.B. Schwadron	
Sheet	2	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear			
Initials*	No.1	Number-Kind Code		Applicant of once occurrent	Figures Appear			
	-	1						
		-						

		FOREI	GN PATENT	DOCUMENTS		_
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	,.e
Examiner Initials*	No.	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (F known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	Ľ
	B7	WO-94/10332-A1	05-11-1994	Medarex, Inc.		<u>L</u>
	В8	WO-95/15340-A1	06-08-1995	The Board of Trustees of Leland Stanford Junior University		L
	B9	WO-96/23882-A1	08-08-1996	The Rockefeller University		ᆫ
	B10	WO-97/45449-A1	12-04-1997	Hart, Derek et al.		╙
	B11	WO-98/24884-A1	06-11-1998	Genpharm International		L
	B12	WO-98/15579-A1	04-16-1998	Canterbury Health Limited		L

\*EXAMINEE: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered, include copy of this form with next communication to applicant. \*CITE NO. Those application(x) which are marked with an single estimation to the Cite No are on supplied (under 37 CFR 1.36(x)/x)) because that speciation was filled effer Juve 30, 200.30 in a wastable in the Applicant's Applicant's are considered to a sensitial to the single sensitial to application was filled effer Juve 30, 200.30 in a wastable in the International Control of the Cite No. 1 (SPTO Patent Documents at www.upsic.ago or MPEP 90 D.A. E. C. T. Applicant's the document, by the wheter took (WPEO Stands 43.). \*For justments patent document, be indication of the Cite No. 1 (SPTO Patent Document and the Cite

Examiner

Signature

/Ronald Schwadron/

Date

Considered

05/19/2010

Approved for use through 12/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Cut	stitute for form 1449/PTO			Complete if Known		
Suc	stitute ioi ioiiii 1440ii 10			Application Number	09/925,284-Conf. #2660	
l IN	IFORMATIO	N DI	SCLOSURE	Filing Date	August 9, 2001	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Daniel Hawiger	
	.,			Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	R.B. Schwadron	
Sheet	3	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant			
Initials*	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear			
	├—							
	_							
	1							
	-							
	-							
	<u> </u>							
	1	1	1					

		FOREI	GN PATENT	DOCUMENTS		_
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	τ°
	B13	WO-99/02562-A1	01-21-1999	Schering Corporation		
	B14	WO-99/16455-A1	04-08-1999	The Austin Research Institute		L
	B15	WO-99/24554-A2	05-20-1999	Univerity of Pittsburgh		L
	B16	WO-99/47673-A2	09-23-1999	Schering Corporation		L
	B17	WO-99/55369-A1	11-04-1999	Smithkline Beecham Corporation		L
	B18	WO-99/58678-A2	11-18-1999	Micromet GmbH		L

Examiner Date Considered 05/19/2010			
	Examiner Signature	/Ronald Schwadron/	05/19/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, includes copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an airgie saterist. () next to the Cite No. are not supplied (under 37 CPR 1984);(2)(w) because that application (extended a unalized in the saterial saterial in the control of the cite No. are not supplied (under 37 CPR 1984);(2)(w) because that application extended a unalized as a validate in the Note that the control of the control of the control of the Note that is supplied to the control of the Note that the Note tha

Approved for use through 12/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid UNIS collection and							
-	stitute for form 1449/PTO			Complete if Known			
Sub	strute for form 1449/F10			Application Number	09/925,284-Conf. #2660		
IN	FORMATION	I DI	SCLOSURE	Filing Date	August 9, 2001		
	TATEMENT I			First Named Inventor	Daniel Hawiger		
_				Art Unit	1644		
	(Use as many sh	eets as	necessary)	Examiner Name	R.B. Schwadron		
Sheet	4	of	12	Attorney Docket Number	RUJ-001CNCPRCE2		

			U.S. PATEN	IT DOCUMENTS	
Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	-				
	-				
	-				
	-				
	+				
	-	<del>                                     </del>			

		FOREI	GN PATENT	DOCUMENTS		_
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	١,
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (# known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	Ľ
	B19	WO-00/00156-A2	01-06-2000	Trustees of Dartmouth College		L
	B20	WO-00/00592-A1	01-06-2000	Bae, Yong Soo et al.		L
	B21	WO-00/18803-A2	04-06-2000	Schering Corporation		Ļ
	B22	WO-00/63251-A1	10-26-2000	Katholieke Universiteit Nijmegen		L
	B23	WO-01/25492-A1	04-12-2001	Biosite Diagnostics Inc. et al.		Ļ
	B24	WO-01/85798-A2	11-15-2001	Medarex, Inc.		L

Examiner	/Ronald Schwadron/	Date Considered	05/19/2010
Signature			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of his form with next communication to applicant. \*OTE NO.: Those application(s) which are marked with an angue satients (?) next to the Cite No. are not supplied under 37 CPR 1986/g/(s)) because that application was filled at use 30,200 is a evaluate in the nangue satients (?) next unique clation designation number (optional). \*See Kinds Codes of USF10 Parter Documents at <a href="https://documents.org/not/">https://documents.org/not/</a> (Applicant Codes of USF10 Parter Documents at <a href="https://documents.org/not/">https://documents.org/not/</a> (Applicant Codes). \*See Kinds Codes of USF10 Parter Documents at <a href="https://documents.org/not/">https://documents.org/not/</a> (Applicant Codes). \*Applicant Codes of the second codes of the codes

Approved for use through 12/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Cubati	tute for form 1449/PT	^		Complete if Known		
Substit	tate for form 144an 1	0		Application Number	09/925,284-Conf. #2660	
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	August 9, 2001	
ST	ATEMENT	BY A	PPLICANT	First Named Inventor	Daniel Hawiger	
٠.				Art Unit	1644	
	(Use as many	sheets as n	ecessary)	Examiner Name	R.B. Schwadron	
Sheet	5	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	D. Minetion Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials* No.1	No.1	Number-Kind Code <sup>2</sup> ( if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	
	_					
	-					
	_					
	-					
	<u> </u>					

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	т
	B25	WO-03/040169-A2	05-15-2003	Medarex Inc et al.		
	B26	WO-04/026326-A2	04-01-2004	Stichting Katholieke Universiteit		L
						L
						┞
						H

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010

"EXAMMEE: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with rest communication to applicant." CITE NO. Those application(s) which are marked with an single saferist (?) rest to the Cite No. are not supplied, under 37 CFR. 1946/1942(19) because that application was 18fe after June 30, 203 of a available in the single saferist (?) rest unique citation designation number (optional). "See Kinds Codes of USPTO Patient Documents at <a href="https://www.usplication.org/">https://www.usplication.org/</a> (In the Codes). "See Kinds Codes of USPTO Patient Documents at <a href="https://www.usplication.org/">https://www.usplication.org/</a> (IN The Codes). "Applicant's the document, the indication of the property of the codes of the second number of the patient document." Kind of document by the appropriate part document, in the indication of the document or use of the second number of the patient document." Kind of document by the appropriate granted as indicated on the document under WiPO Standard ST. 16.4 possible. "Applicant is to place a choice make true? Explaint harquage Translation is allabele."

Approved for use through 12/31/2006. OMB 0051-0031
U.S. Patent and Trademark Office; U.S. DEFARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEFARTMENT OF COMMENT
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless or contains a valid Office of which control number.

	stitute for form 1449/PTC			Complete if Known		
Sub	Substitute for form 1449/F10			Application Number	09/925,284-Conf. #2660	
110	IFORMATIO	N DI	SCLOSURE	Filing Date	August 9, 2001	
	STATEMENT BY APPLICANT			First Named Inventor	Daniel Hawiger	
٠	IAILMENT			Art Unit	1644	
	(Use as many s	heets a	necessary)	Examiner Name	R.B. Schwadron	
Sheet	6	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	Apostolopoulos, Vasso et al, "Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses," Vaccine, Vol. 18:3174-3184 (2000)	
	C2	Berard, Frederic et al, "Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Matanoma Cells," <i>J. Exp. Med.</i> , Vol. 192(11):1535-1543 (2000)	
	СЗ	Berlyn, Kathleen A. et al, "Generation of CD4* and CD8* T Lymphocyte Responses by Dendritic Cells Armed with PSA/nti-PSA (Antigen/Antibody) Complexes," Clinical Immunology, Vol. 101(3):278-283 (2001)	
	C4	Bird, Robert E. et al, "Single-Chain Antigen-Binding Proteins," Science, Vol. 242(4877):423-426 (1988)	
	C5	Brennan, Maureen et al, "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G <sub>1</sub> Fragments," <i>Science</i> , Vol. 229:81-83 (1985)	_
	C6	Casset, Florence et al., "A peptide mimetic of an anti-CD4 monoclonal antibody in rational design," Biochemical and Biophysical Research Communications, Vol. 307:198-205 (2003)	L

Examiner Signature	/Ronald Schwadron/	*	Date Considered	05/19/2010
	and the second s	et citation is in conformance with MPEP 609.	Draw line through ci	tation if not in conformance and not

Date

"EXAMINER. Initial if reference considered, whether or not clation is in conformance with MPEP 600. Draw line through clieds of in or conformance and not considered, include copy of this form with need communication to applicant." CITE No. Those document(s) which are catasited with an double activist, "I need to the Cite No. are not supplied Decause they were previously cited by or submitted to the Office in a prior application relied upon in this application for an arisefficial from the Cite No. are not supplied Decause they were previously cited by or submitted to the Office in a prior application relied upon in this application for an arisefficial from the Cite No. are not supplied Decause they were previously cited by or submitted to the Office in a prior application relied upon in this application for an arisefficial from the Cite No. are not supplied Decause they were previously cited by or submitted to the Office in a prior application relied upon in this application for an arisefficial from the Cite No. The C

Examiner

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

PTO/SB06b (11-08)
Approved for use through 12/31/2006. DM6 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of intermisement sented set Contains a valid CMB counter number.

	Substitute for form 1449/PTO			Complete if Known		
Sub	sutute for form 1449/FTC	,		Application Number	09/925,284-Conf. #2660	
IN	FORMATIO	N DIS	CLOSURE	Filing Date	August 9, 2001	
	STATEMENT BY APPLICANT			First Named Inventor	Daniel Hawiger	
Ŭ	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1644	
	(Use as many	sheets as r	necessary)	Examiner Name	R.B. Schwadron	
Sheet	7	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C7	Chen, Yvonne et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody. Crystal Strucutre of an Affinity-matured Fab in Complex with Antigen," <i>J. Mol. Biol.</i> , Vol. 293:865-881 (1999)	L
	C8	Chien, Nadine C. et al, "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)	
	С9	Cox, John C. et al., "Adjuvants - a classification and review of their modes of action," Vaccine,	
	C10	De Pascalis, Roberto et al., "Graffing of 'Abbreviated' Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," <i>The Journal of Immunology</i> , Vol. 169:3076-3084 (2022)	
	C11	Frieta, Davor et al, "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo," <i>International Immunopharmacology</i> , Vol. 1:265-275 (2001)	
	C12	Galfre, G. et al, "Antibodies to major histocompatibility antigens produced by hybrid cell lines," Nature, Vol. 266(7):550-552 (1977)	

Examiner Signature	/Ronald Schwadron/	Dat Cor	te nsidered	05/19/2010

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "" CITE NO.. Those document(s) which are marked with an double saterisk ("") nost to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 12913000. OMB 0551-0011

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a wall OMB count number.

0	Substitute for form 1449/PTO			Complete if Known		
Suc	istitute ioi ioini 1443ii 10			Application Number	09/925,284-Conf. #2660	
11	FORMATION	l Di	SCLOSURE	Filing Date	August 9, 2001	
	STATEMENT BY APPLICANT			First Named Inventor	Daniel Hawiger	
_	174121112111			Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	R.B. Schwadron	
Sheet	8	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C13	Geissmann, Frédéric et al, "A Subset of Human Dendritic Cells Expresses IgA Fc Receptor (CD89), Which Mediates Internalization and Activation Upon Cross-Linking by IgA Complexes," The Journal of Immunology, Vol. 166:346-352 (2001)	
	C14	Glennie, Martin J. et al, "Preparation and Performance of Bispecific F(ab')2 Antibody Containing Thioether-Linked Fab'y Fragments," <i>The Journal of Immunology</i> , Vol. 139(7):2367- 2375 (1987)	
	C15	Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (2001)	L
	C16	He, Li-Zhen et al, "A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor- Associated Antigen, Human Chorionic Gonadotropin §," Clinical Cancer Research, Vol. 10:1920-1927 (2004)	
	C17	He, Lizhen et al, "An Antigen Presenting Cell-Targeted Cancer Vaccine that Elicits CD4 and CD8 Effector Responses to the hCGj Tumor-Associated Antigen," Proceedings of the American Association for Cancer Research, Vol. 44, 2nd ed., pg. 167 (2003)	
	C18	Janeway, Charles A. Jr. et al., "Localized regions of hypervariable sequence form the antigen- binding site," <i>Immunobiology</i> , 6 <sup>th</sup> Edition, Garland Science, Chpt. 3, pgs. 110-112 (2004)	L

Examiner	/Ronald Schwadron/	Date Considered	05/19/2010
Signature	/ Toriala Contrastors	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "\*CITE NO." Those document(s) which are marked with an double asterisk (") next to the Cite No. are not supplied focuses they were previously cited by or submitted to the Office in a prior application relied upon in this application for an antier filing date under 3 by U.S. 120.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

05/19/2010

PTO/SB08e (11-08)
Approved for use through 12/31/2008. ONE 081-081-093
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless 15 colorans a valled Office content

Date

	o for form 1449/PT	^		Complete if Known		
Substitute	9 for form 1449/P1	U		Application Number	09/925,284-Conf. #2660	
INFO	ORMATIC	ON DIS	CLOSURE	Filing Date	August 9, 2001	
STATEMENT BY APPLICANT				First Named Inventor	Daniel Hawiger	
017		D. 74.	. 2.07	Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	R.B. Schwadron	
Sheet	9	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C19	Karpovsky, Boris et al, "Production of Target-Specific Effector Cells Using Hetero-Cross- Linked Aggregates Containing Anti-Target Cell and Anti-Fcy Receptor Antibodies," <i>Journal of Experimental Medicine</i> , Vol. 160:1686-1701 (1984)	
	C20	Kawakami, Yutaka et al, "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma." Journal of Immunotherapy, Vol. 21(4):237-246 (1998)	
	C21	Kobayashi, Hiroyuki et al, "Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody," <i>Protein Engineering</i> , Vol. 12(10):879-884 (1999)	
	C22	Lamminmäki, Urpo et al., "Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17th-Estradiol," The Journal of Biological Chemistry, Vol. 276(39):36687-36694 (2001)	L
	C23	Liu, Margaret A. et al, "Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes." <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82:8648-8652 (1985)	L
	C24	Lonberg, Nils et al, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications." <i>Nature</i> , Vol. 368:856-859 (1994)	L
5	C25	MacCallum, Robert M. et al., "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography," J. Mol. Biol., Vol. 262:732-745 (1996)	

[S	gnature /nonaid ochwadion/	Continuence	CO-IVIEDIU
c	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, presidered. Include copy of this form with next communication to applicant. "CITE NO.: Those docu- ext to the Cite No, are not supplied because they were previously cited by or submitted to the Office I ratire fifting date under 35 U.S.C. 120.		

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

(Donald Cobwadoon)

Examiner

Approved for use through 12/3/12/06.0 MB 0691-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and U.S. DEPARTMENT OF COMMENT
U.S. DEPARTMENT OF U.S. DEPARTMENT
U.S. DEPARTMENT

Cultura	Substitute for form 1449/PTO			Complete if Known		
Subst			Application Number	09/925,284-Conf. #2660		
IN	FORMATION	ON DISC	CLOSURE	Filing Date	August 9, 2001	
SI	STATEMENT BY APPLICANT			First Named Inventor	Daniel Hawiger	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	R.B. Schwadron	
Sheet	10	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C26	Monteiro, Renato C. et al, "Molecular Heterogeneity of Fcα Receptors Detected by Receptor- Specific Monoclonal Antibodies," The Journal of Immunology, Vol. 148(6):1764-1770 (1992)	
	C27	Noorman, Femke et al. "Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages," <i>Journal of Leukocyte Biology</i> , Vol. 61:63-72 (1997)	
	C28	Nouri-Shirazi, Mahyar et al, "Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Response," <i>The Journal of Immunology</i> , Vol. 165:3797-3803 (2000)	
	C29	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies," Behring Inst. Mitt., Vol. 78:118-132 (1985)	
	C30	Potter, Kathleen N. et al, "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-344-Encoded Igs in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)	

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010

EXAMNER; initial if reference considered, whether or as calation is in conformance with MERE 600. Does his hybridge intended to conditional, include caper, and include caper and include caper

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 12/3/12/006. DMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of internation unless its continuin a valled DMS control number.

	Substitute for form 1449/PTO			Complete if Known		
Subst	itute for form 1449/F	10		Application Number	09/925,284-Conf. #2660	
IN	FORMATION	ON DISC	CLOSURE	Filing Date	August 9, 2001	
	STATEMENT BY APPLICANT			First Named Inventor	Daniel Hawiger	
٠.	A . L			Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	R.B. Schwadron	
Sheet	11	of	12	Attorney Docket Number	RUJ-001CNCPRCE2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C31	Ramakrishna, Vanky et al, "Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules," <i>The</i> <i>Journal of Immunology</i> , Vol. 172:2845-2852 (2004)	
	C32	Ramakrishna, Venky et al, "Synergistic Role of TLR Agonists in T Cell-Mediated Immunity Induced by Mannose Receptor Antibody Targeting of Tumor Antigens to Human DCs," J. //mmunother., Vol. 28(6):658 (2005)	
	C33	Rudikoff, Stuart et al, "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA, Vol. 79:1979-1983 (1982)	Ĺ
	C34	Sallusto, Federica et al, 'Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment Downregulation by Cytokines and Bacterial Products," J. Exp. Med., Vol. 182:389-400 (1995)	
	C35	Schjetne, Karoline W. et al., "Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors," <i>The Journal of Immunology</i> , Vol. 178:4169-4176 (2007)	
	C36	Taylor, Lisa D. et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," <i>Nucleic Acids Research</i> , Vol. 20(23):6287-6295 (1992)	

Examiner	Date	- 1
Signature //Ronald Schwadron/	Considered 05/19/2010	_

EXAMINER, Initial if reference considered, whether one caption is in conformance with MERE 000. Done the through citation if not in conformance with MERE 000. Done the through citation if not in conformance with MERE 000. The reference is with a remainded with an ordinal seatests, (\*\*) could be the Citation of the Ci

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached

PTO/SB089 (11-08)
Approved for use though 12/31/2008. 000 8095-0031
U.S. Palent and Trademax Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information untest & Columnia re-valled 008 control number.

Substitute for form 1449/PTO		Complete if Known			
Strange of four twent to				Application Number	09/925,284-Conf. #2660
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			LOSURE	Filing Date	August 9, 2001
				First Named Inventor	Daniel Hawiger
				Art Unit	1644
(Use as many sheets as necessary)		Examiner Name	R.B. Schwadron		
Sheet	12	of	12	Attorney Docket Number	RUJ-001CNCPRCE2

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C37	Tempest, Philip R. et al, "A Humanized Anti-Tumor Necrosis Factor-α Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)	
	C38	Tjoa, Benjamin A. et al, "Development of dendritic-cell based prostate cancer vaccine," Immunology Letters, Vol. 74:87-93 (2000)	
	C39	Tüting, Thomas et al, "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN-a," The Journal of Immunotherapy, Vol. 160:1139-1147 (1998)	
	C40	Wallace, Paul K. et al, "Exogenous antigen targeted to FcγRI on Myeloid cells is presented in association with MHC class I," <i>Journal of Immunological Methods</i> , Vol. 248:183-194 (2001)	L
	C41	Wang, Hul et al, "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization," PNAS, Vol. 96(2):847-852 (2000)	
	C42	Ward, E. Sally et al, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli," Nature, Vol. 341:544-546 (1989)	
	C43	You, Zhaoyang et al, "Targeting Dendritic Cells to Enhance DNA Vaccine Potency," Cancer Research, Vol. 61:3704-3711 (2001)	

Examiner Signature	/Ronald Schwadron/	Date Considered	05/19/2010
considered.	Initial if reference considered, whether or not clation is in confinctude copy of this form with next communication to applicant. te No. are not supplied because they were previously cited by also under 35 U.S.C. 120.		

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.